MSD 4280-003
This study will evaluate the safety and efficacy of favezelimab (MK-4280) in combination with pembrolizumab (MK-3475) using a non-randomised study design in participants with the following haematological malignancies:
This study will also evaluate the safety and efficacy of pembrolizumab or favezelimab administered as monotherapy in participants with cHL using a 1:1 randomised study design.
The study will have 2 phases: a safety lead-in and an efficacy expansion phase. The recommended Phase 2 dose (RPTD) will be determined in the safety lead-in phase by evaluating dose-limiting toxicities.
There is no primary hypothesis for this study.
CLINICALTRIALS.GOV IDENTIFIER:
NCT03598608
When speaking to your doctor, please have the trial identifier number available.
Tests the medicine or vaccine in a small group of 20 to 100 volunteers who are usually healthy, but not always. The trial often takes place in a hospital.
Tests the medicine or vaccine in approximately 100 to 500 volunteers. In the case of medicines, volunteers usually have the disease or condition the investigational medicine is designed to treat. In vaccine studies, the volunteers are usually healthy.
Dates
Only a qualified healthcare professional can determine your eligibility. However, this information may be useful in starting a conversation with your doctor.
Conditions
Hodgkin Disease, Lymphoma, B-Cell, Lymphoma, Non-Hodgkin
Age Range
18 - No Age Maximum
Sex
All
Locations provided may not reflect the most current site information. Please call the number provided in the location results to confirm.
Print this page
Email this page